RxDoctor Payments Data

Rahman Subrati, MD

Family Medicine · Montville, NJNPI 1932479094

Payments from drug & device makers

$3,542in general payments, 2019–2025

Across 214 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$689
  • Novo Nordisk$624
  • Lilly USA, LLC$481
  • Pfizer$420
  • GSK$251
  • AbbVie$209
  • plus $868 from 20 others

What the payments were for

  • Food & beverage$3,533100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,542 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$183,489
Medicare patients
348
Services billed
2,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$78,258
JanuviaSitagliptin Phosphate41$51,673
JardianceEmpagliflozin31$36,575
EliquisApixaban13$18,056
TradjentaLinagliptin17$15,278
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,566
VascepaIcosapent Ethyl12$4,213
Rosuvastatin Calcium244$4,004
SynthroidLevothyroxine Sodium47$3,685
Levothyroxine Sodium206$2,476
Atorvastatin Calcium250$2,246
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid33$2,168
Metformin Hcl ErMetformin Hcl158$2,045
Telmisartan45$1,689
Niacin ErNiacin23$1,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$624$78,25861 claims
Boehringer IngelheimJardiance, Tradjenta$36$51,85448 claims
PfizerEliquis$420$18,05613 claims
AstraZenecaBreztri Aerosphere$689$12,56620 claims
AbbVieSynthroid$209$3,68547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Montville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →